Guía para el manejo de los síntomas menopáusicos en mujeres con cáncer de mama
Barra lateral del artículo
Contenido principal del artículo
Resumen
.
Downloads
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Bordeleau l, Pritchard K, Goodwin P, et al. therapeutic options for themanagement of hot flashes in breast cancer survivors: an evidence-based review.clin ther. 2007;29(2):230-41. DOI: https://doi.org/10.1016/j.clinthera.2007.02.006
carpenter Js, Johnson d, Wagner l, et al. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. oncol nurs Forum. 2002;29(3):e16-25 DOI: https://doi.org/10.1188/02.ONF.E16-E25
Harris PF, remington Pl, trentham-dietz a, et al. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain symptom Manage. 2002;23(6):501-9 DOI: https://doi.org/10.1016/S0885-3924(02)00395-0
Kronenberg F. Hot flashes: epidemiology and physiology. ann n Y acad sci. 1990;592:52-86; discusión 123-33. DOI: https://doi.org/10.1111/j.1749-6632.1990.tb30316.x
Goodwin PJ, ennis M, Pritchard Ki, et al. risk of menopause during the first year after breast cancer diagnosis. J clin oncol. 1999;17(8):2365-70. DOI: https://doi.org/10.1200/JCO.1999.17.8.2365
Mortimer Je. Hormone replacement therapy and beyond. the clinical challenge of menopausal symptoms in breast cancer survivors. Geriatrics. 2002;57(9):25-31
cella d, Fallowfield lJ. recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast cancer res treat. 2008;107(2):167-80. DOI: https://doi.org/10.1007/s10549-007-9548-1
Fellowes d, Fallowfield lJ, saunders cM, et al. tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments? Breast cancer res treat. 2001;66(1):73-81. DOI: https://doi.org/10.1023/A:1010684903199
Barron ti , connolly r, Bennett K, et al. early discontinuation of tamoxifen: a lesson for oncologists. cancer. 2007;109(5):832-9. DOI: https://doi.org/10.1002/cncr.22485
canney Pa, Hatton MQ. the prevalence of menopausal symptoms in patients treated for breast cancer. clin oncol ( r coll radiol). 1994;6(5):297-9. DOI: https://doi.org/10.1016/S0936-6555(05)80270-5
schover lr . sexuality and body image in younger women with breast cancer. J natl cancer inst Monogr. 1994;(16):177-82.
ockene JK, Barad dH, cochrane BB, et al. symptom experience after discontinuing use of estrogen plus progestin. JaMa. 2005;294(2):183-93. DOI: https://doi.org/10.1001/jama.294.2.183
Pérez dG, Zahasky KM, loprinzi cl , et al. tamoxifen-associated hot flashes in women. support cancer ther. 2007;4(3):152-6. DOI: https://doi.org/10.3816/SCT.2007.n.009
Goodwin PJ, ennis M, Pritchard Ki, et al. risk of menopause during the first year after breast cancer diagnosis. J clin oncol. 1999;17(8):2365-70 DOI: https://doi.org/10.1200/JCO.1999.17.8.2365
Madalinska JB, van Beurden M, Bleiker eM, et al. the impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J clin oncol. 2006;24(22): 3576-82 DOI: https://doi.org/10.1200/JCO.2005.05.1896
Howell a, cuzick J, Baum M, et al. results of the atac ( arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. lancet. 2005;365(9453):60-2 DOI: https://doi.org/10.1016/S0140-6736(04)17666-6
Burwell sr , case ld , Kaelin c, et al. sexual problems in younger women after breast cancer surgery. J clin oncol. 2006;24(18):2815-21 DOI: https://doi.org/10.1200/JCO.2005.04.2499
Fobair P, stewart sl , chang s, et al. Body image and sexual problems in youngwomen with breast cancer. Psychooncology. 2006;15(7):579-94. DOI: https://doi.org/10.1002/pon.991
Hilditch Jr, lewis J, Peter a, et al. a menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996;24(3):161-75. errata en: Maturitas. 1996;25(3):231. DOI: https://doi.org/10.1016/S0378-5122(96)01082-1
Hickey M, saunders cM, stuckey BG. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. lancet oncol. 2005;6(9):687-95. DOI: https://doi.org/10.1016/S1470-2045(05)70316-8
Kronenberg F, Fugh-Berman a. complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. ann intern Med. 2002;137(10):805-13 DOI: https://doi.org/10.7326/0003-4819-137-10-200211190-00009
antoine c, liebens F, carly B, et al. safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. climacteric. 2007:10(1): 23-6. DOI: https://doi.org/10.1080/13697130601176734
spence dW, Kayumov l, chen a, et al. acupuncture increases nocturnal melatonin secretion and reduces insomnia and anxiety: a preliminary report. J neuropsychiatry clin neurosci. 2004;16(1):19-28. DOI: https://doi.org/10.1176/appi.neuropsych.16.1.19
Maclennan aH, Broadbent Jl, lester s, et al. oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. cochrane database syst rev. 2004;(4):cd 002978. DOI: https://doi.org/10.1002/14651858.CD002978.pub2
sestak i, Kealy r, edwards r, et al. influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J clin oncol. 2006;24(24):3991-6. DOI: https://doi.org/10.1200/JCO.2005.04.3745
rossouw Je, anderson Gl, Prentice rl , et al. risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health initiative randomized controlled trial. JaMa. 2002;288(3):321-33. DOI: https://doi.org/10.1001/jama.288.3.321
anderson Gl, limacher M, assaf ar , et al. effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health initiative randomized controlled trial. JaMa. 2004;291(14):1701-12. DOI: https://doi.org/10.1001/jama.291.14.1701
conner P. Breast response to menopausal hormone therapy-aspects on proliferation, apoptosis and mammographic density. ann Med. 2007;39(1):28-41 DOI: https://doi.org/10.1080/07853890601039842
Holmberg l, anderson H; HaBits steering and data monitoring committees. HaBits (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. lancet. 2004;363(9407):453-5. DOI: https://doi.org/10.1016/S0140-6736(04)15493-7
von schoultz e, rutqvist le ; stockholm Breast cancer study Group. Menopausal hormone therapy after breast cancer: the stockholm randomized trial. J natl cancer inst. 2005;97(7):533-5. DOI: https://doi.org/10.1093/jnci/dji071
loprinzi cl , Michalak Jc, Quella sK, et al. Megestrol acetate for the prevention of hot flashes. n engl J Med. 1994;331(6):347-52. DOI: https://doi.org/10.1056/NEJM199408113310602
Bertelli G, venturini M, del Mastro l, et al. intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. ann oncol. 2002;13(6):883-8. DOI: https://doi.org/10.1093/annonc/mdf151
Quella sK, loprinzi cl , sloan J a, et al. long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. cancer. 1998;82(9):1784-8. DOI: https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9<1789::AID-CNCR27>3.3.CO;2-B
eden J. Progestins and breast cancer. am J obstet Gynecol. 2003;188(5):1123-31. DOI: https://doi.org/10.1067/mob.2003.201
tibolone: a review of clinical studies. BJ oG. 1999;106(suppl 19).
albertazzi P, di Micco r, Zanardi e. tibolone: a review. Maturitas. 1998;30(3):295-305. DOI: https://doi.org/10.1016/S0378-5122(98)00059-0
Kloosterboer HJ, sands r. intracrinology: the secret of the tissue-specificity of tibolone. J Br Menopause soc. 2000;6(suppl):23-7. DOI: https://doi.org/10.1177/13621807990050S106
valdivia i, ortega d. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. clin drug invest. 2000;20(2):101-7. DOI: https://doi.org/10.2165/00044011-200020020-00005
landgren MB, Bennink HJ, Helmond Fa, et al. dose-response analysis of effects of tibolone on climacteric symptoms. BJoG. 2002;109(10):1109-14. DOI: https://doi.org/10.1111/j.1471-0528.2002.02020.x
Kenemans P, Bundred nJ, Foidart JM, et al. safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. lancet oncol. 2009;10(2):135-46 DOI: https://doi.org/10.1016/S1470-2045(08)70341-3
newton KM, reed sd , lacroix aZ, et al. treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. ann intern Med. 2006;145(12):869-79. DOI: https://doi.org/10.7326/0003-4819-145-12-200612190-00003
Kronenberg F, Fugh-Berman a. complementary and alternative medicine formenopausal symptoms: a review of randomized, controlled trials. ann intern Med. 2002;137(10):805-13 DOI: https://doi.org/10.7326/0003-4819-137-10-200211190-00009
Barton dl , loprinzi cl , Quella sK, et al. Prospective evaluation of vitamin e for hot flashes in breast cancer survivors. J clin oncol. 1998;16(2):495-500. DOI: https://doi.org/10.1200/JCO.1998.16.2.495
Pockaj Ba, Gallagher JG, loprinzi cl , et al. Phase iii double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: ncct G trial n01 cc 1. J clin oncol. 2006;24(18):2836-41 DOI: https://doi.org/10.1200/JCO.2005.05.4296
Belardo a, salort F, lamm M, et al. nuestra experiencia con cimicifuga racemosa en el tratamiento del síndrome climatérico en mujeres postmenopáusicas. Presentado en: 4as Jornadas argentinas de climaterio. 2003 ago 15-16; salta, argentina
lorusso a, Belardo a. isoflavonas y su acción sobre la mama. revista sae Gre . 2004;11(3).
Belardo M, Molina r. tratamiento del síndrome climatérico con isoflavonas estandarizadas de soja en la postmenopausia. revista F.a.s.G. o. 2005;4(1).
the role of isoflavones in menopausal health: consensus opinion of the north american Menopause society. Menopause. 2000;7(4):215-29. DOI: https://doi.org/10.1097/00042192-200007040-00003
nikander e, Kilkkinen a, Metsä-Heikkilä M, et al. a randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. obstet Gynecol. 2003;101(6):1213-20. DOI: https://doi.org/10.1097/00006250-200306000-00014
antoine c, liebens F, carly B, et al. safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. climacteric. 2007:10(1): 23-6. DOI: https://doi.org/10.1080/13697130601176734
nelson Hd, vesco KK, Haney e, et al. nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JaMa. 2006;295(17):2057-71. DOI: https://doi.org/10.1001/jama.295.17.2057
Quella sK, loprinzi cl , Barton dl , et al. evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a north central cancer treatment Group trial. J clin oncol. 2000;18(5):1068-74. DOI: https://doi.org/10.1200/JCO.2000.18.5.1068
Goldberg rM, loprinzi cl , o’Fallon Jr, et al. transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J clin oncol. 1994;12(1):155-8. errata en: J clin oncol 1996;14(8):2411. DOI: https://doi.org/10.1200/JCO.1994.12.1.155
Pandya KJ, raubertas rF, Flynn PJ, et al. oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a university of rochester cancer center community clinical oncology Program study. ann intern Med. 2000;132(10):788-93. DOI: https://doi.org/10.7326/0003-4819-132-10-200005160-00004
rapkin aJ. vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. am J obstet Gynecol. 2007;196(2):97-106. DOI: https://doi.org/10.1016/j.ajog.2006.05.056
stearns v. clinical update: new treatments for hot flushes. lancet. 2007;369(9579):2062-4. DOI: https://doi.org/10.1016/S0140-6736(07)60959-3
speroff l, Gass M, constantine G, et al. efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. obstet Gynecol. 2008;111(1):77-87. DOI: https://doi.org/10.1097/01.AOG.0000297371.89129.b3
loprinzi cl , Kugler JW, sloan J a, et al. venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. lancet. 2000;356(9247):2059-63. DOI: https://doi.org/10.1016/S0140-6736(00)03403-6
lugones l, Belardo a, tutzer M, et al. venlafaxina para el manejo de los sofocos (trabajo preliminar). Presentado en: 4as Jornadas argentinas de climaterio. 2003 ago 15-16; salta, argentina.
stearns v. clinical update: new treatments for hot flushes. lancet. 2007;369(9579):2062-4. DOI: https://doi.org/10.1016/S0140-6736(07)60959-3
loprinzi cl , sloan J a, Perez ea , et al. Phase iii evaluation of fluoxetine for treatment of hot flashes. J clin oncol. 2002;20(6):1578 DOI: https://doi.org/10.1200/JCO.20.6.1578
loprinzi cl , Flynn PJ, carpenter la , et al. Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med. 2005;8(5): 924-30. DOI: https://doi.org/10.1089/jpm.2005.8.924
suvanto-luukkonen e, Koivunen r, sundström H, et al. citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause. 2005;12(1):18-26. DOI: https://doi.org/10.1097/00042192-200512010-00006
stearns v, Beebe Kl, iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JaMa. 2003;289(21):2827-34. DOI: https://doi.org/10.1001/jama.289.21.2827
stearns v, slack r, Greep n, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J clin oncol. 2005;23(28):6919-30. errata en: J clin oncol. 2005;23(33):8549. DOI: https://doi.org/10.1200/JCO.2005.10.081
Gordon Pr, Kerwin JP, Boesen KG, et al. sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause. 2006;13(4):568-75. DOI: https://doi.org/10.1097/01.gme.0000196595.82452.ca
Grady d, cohen B, tice J, et al. ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. obstet Gynecol. 2007;109(4):823-30. DOI: https://doi.org/10.1097/01.AOG.0000258278.73505.fa
Kerwin JP, Gordon Pr, senf JH. the variable response of women with menopausal hot flashes when treated with sertraline. Menopause. 2007;14(5):841-5 DOI: https://doi.org/10.1097/gme.0b013e31802e7f22
Perez dG, loprinzi cl , Barton dl , et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J support oncol. 2004;2(1):50-6.
Biglia n, Kubatzki F, sgandurra P, et al. Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial. Breast J. 2007;13(5):490-5. DOI: https://doi.org/10.1111/j.1524-4741.2007.00470.x
stearns v, Johnson Md, rae JM, et al. active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J natl cancer inst. 2003;95(23):1758-64. DOI: https://doi.org/10.1093/jnci/djg108
alfaro cl , lam YW, simpson J, et al. cYP2 d6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J clin Pharmacol. 2000;40(1):58-66. DOI: https://doi.org/10.1177/00912700022008702
Jin Y, desta Z, stearns v, et al. cYP2 d6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J natl cancer inst. 2005;97(1):30-9. DOI: https://doi.org/10.1093/jnci/dji005
reddy sY, Warner H, Guttuso t Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. obstet Gynecol. 2006;108(1):41-8 DOI: https://doi.org/10.1097/01.AOG.0000222383.43913.ed
Pandya KJ, thummala ar , Griggs JJ, et al. Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast cancer res treat. 2004;83(1):87-9. DOI: https://doi.org/10.1023/B:BREA.0000010676.54597.22
Pandya KJ, Morrow Gr, roscoe Ja, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. lancet. 2005;366(9488):818-24 DOI: https://doi.org/10.1016/S0140-6736(05)67215-7
Guttuso t Jr, Kurlan r, Mc dermott MP, et al. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. obstet Gynecol. 2003;101(2):337-45. DOI: https://doi.org/10.1097/00006250-200302000-00022
Butt da , lock M, lewis Je, et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008;15(2):310-8 DOI: https://doi.org/10.1097/gme.0b013e3180dca175
loprinzi cl , Kugler JW, Barton dl , et al. Phase iii trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: ncct G n03 c5. J clin oncol. 2007;25(3):308-12. DOI: https://doi.org/10.1200/JCO.2006.07.5390
norton JW. Gabapentin withdrawal syndrome. clin neuropharmacol. 2001;24(4):245-6 DOI: https://doi.org/10.1097/00002826-200107000-00011
Fallowfield l, cella d, cuzick J, et al. Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (atac ) adjuvant Breast cancer trial. J clin oncol. 2004;22(21):4261-71. DOI: https://doi.org/10.1200/JCO.2004.08.029
Baum M, Buzdar a, cuzick J, et al. anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the atac ( arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. cancer. 2003;98(9):1802-10. DOI: https://doi.org/10.1002/cncr.11745
dew J e, Wren BG, eden J a. a cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. climacteric. 2003;6(1):45-52. DOI: https://doi.org/10.1080/cmt.6.1.45.52
Goss Pe, ingle J n, Martino s, et al. a randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. n engl J Med. 2003;349(19):1793-802. DOI: https://doi.org/10.1056/NEJMoa032312
Kendall a, dowsett M, Folkerd e, et al. caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. ann oncol. 2006;17(4):584-7. DOI: https://doi.org/10.1093/annonc/mdj127
Mathias c, cardeal Mendes cM, Pondé de sena e, et al. an open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. ann oncol. 2006;17(12):1792-6 DOI: https://doi.org/10.1093/annonc/mdl304